Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

BACKGROUND: Peptide vaccines designed to stimulate melanoma-reactive CD4(+) T cells can induce T cell and antibody (Ab) responses, associated with enhanced overall survival. We hypothesized that adding toll-like receptor 3 agonist polyICLC to an incomplete Freund’s adjuvant (IFA) would be safe and w...

Descripción completa

Detalles Bibliográficos
Autores principales: Slingluff, Jr., Craig L, Petroni, Gina R, Chianese-Bullock, Kimberly A, Wages, Nolan A, Olson, Walter C, Smith, Kelly T, Haden, Kathleen, Dengel, Lynn T, Dickinson, Anna, Reed, Caroline, Gaughan, Elizabeth M, Grosh, William W, Kaur, Varinder, Varhegyi, Nikole, Smolkin, Mark, Galeassi, Nadejda V, Deacon, Donna, Hall, Emily H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825263/
https://www.ncbi.nlm.nih.gov/pubmed/33479025
http://dx.doi.org/10.1136/jitc-2020-000934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825263/
https://www.ncbi.nlm.nih.gov/pubmed/33479025
http://dx.doi.org/10.1136/jitc-2020-000934

Ejemplares similares